Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2019 1
2020 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.
Wang J, Calizo A, Zhang L, Pino JC, Lyu Y, Pollard K, Zhang X, Larsson AT, Conniff E, Llosa NJ, Wood DK, Largaespada DA, Moody SE, Gosline SJ, Hirbe AC, Pratilas CA. Wang J, et al. Among authors: larsson at. Sci Adv. 2023 Nov 24;9(47):eadg8876. doi: 10.1126/sciadv.adg8876. Epub 2023 Nov 24. Sci Adv. 2023. PMID: 38000020 Free PMC article.
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
Larsson AT, Bhatia H, Calizo A, Pollard K, Zhang X, Conniff E, Tibbitts JF, Rono E, Cummins K, Osum SH, Williams KB, Crampton AL, Jubenville T, Schefer D, Yang K, Lyu Y, Pino JC, Bade J, Gross JM, Lisok A, Dehner CA, Chrisinger JSA, He K, Gosline SJC, Pratilas CA, Largaespada DA, Wood DK, Hirbe AC. Larsson AT, et al. Neuro Oncol. 2023 Nov 2;25(11):2044-2057. doi: 10.1093/neuonc/noad097. Neuro Oncol. 2023. PMID: 37246765 Free PMC article.
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors.
Williams KB, Larsson AT, Keller BJ, Chaney KE, Williams RL, Bhunia MM, Draper GM, Jubenville TA, Rathe SK, Moertel CL, Ratner N, Largaespada DA. Williams KB, et al. Among authors: larsson at. bioRxiv [Preprint]. 2024 Mar 25:2024.03.25.585959. doi: 10.1101/2024.03.25.585959. bioRxiv. 2024. PMID: 38585724 Free PMC article. Preprint.
Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors.
Beckmann PJ, Larson JD, Larsson AT, Ostergaard JP, Wagner S, Rahrmann EP, Shamsan GA, Otto GM, Williams RL, Wang J, Lee C, Tschida BR, Das P, Dubuc AM, Moriarity BS, Picard D, Wu X, Rodriguez FJ, Rosemarie Q, Krebs RD, Molan AM, Demer AM, Frees MM, Rizzardi AE, Schmechel SC, Eberhart CG, Jenkins RB, Wechsler-Reya RJ, Odde DJ, Huang A, Taylor MD, Sarver AL, Largaespada DA. Beckmann PJ, et al. Among authors: larsson at. Cancer Res. 2019 Mar 1;79(5):905-917. doi: 10.1158/0008-5472.CAN-18-1261. Epub 2019 Jan 23. Cancer Res. 2019. PMID: 30674530 Free PMC article.
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors.
Wang J, Calizo A, Zhang L, Pino JC, Lyu Y, Pollard K, Zhang X, Larsson AT, Conniff E, Llosa N, Wood DK, Largaespada DA, Moody SE, Gosline SJ, Hirbe AC, Pratilas CA. Wang J, et al. Among authors: larsson at. bioRxiv [Preprint]. 2023 Feb 3:2023.02.02.526674. doi: 10.1101/2023.02.02.526674. bioRxiv. 2023. Update in: Sci Adv. 2023 Nov 24;9(47):eadg8876. doi: 10.1126/sciadv.adg8876. PMID: 36778419 Free PMC article. Updated. Preprint.
Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma.
Smeester BA, Draper GM, Slipek NJ, Larsson AT, Stratton N, Pomeroy EJ, Becklin KL, Yamamoto K, Williams KB, Laoharawee K, Peterson JJ, Abrahante JE, Rathe SK, Mills LJ, Crosby MR, Hudson WA, Rahrmann EP, Largaespada DA, Moriarity BS. Smeester BA, et al. Among authors: larsson at. Mol Cancer Ther. 2020 Dec;19(12):2528-2541. doi: 10.1158/1535-7163.MCT-20-0369. Epub 2020 Sep 30. Mol Cancer Ther. 2020. PMID: 32999043 Free PMC article.
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby MR, Wang M, Rahrmann EP, Moriarity BS, Largaespada DA. Smeester BA, et al. Among authors: larsson at. Bone. 2020 Jul;136:115353. doi: 10.1016/j.bone.2020.115353. Epub 2020 Apr 3. Bone. 2020. PMID: 32251854